Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial.

[1]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[2]  R. Califf,et al.  Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. , 1997, The American journal of cardiology.

[3]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[4]  Mintz,et al.  Angiographic Results and Late Clinical Outcomes Utilizing a Stent Synergy (Pre-Stent Atheroablation) Approach in Complex Lesion Subsets. , 1996, The Journal of invasive cardiology.

[5]  P. Teirstein,et al.  Safety and efficacy of extended urokinase infusion plus stent deployment for treatment of obstructed, older saphenous vein grafts. , 1995, The American journal of cardiology.

[6]  R. Califf,et al.  Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). , 1995, Journal of the American College of Cardiology.

[7]  R. Califf,et al.  Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. , 1995, Circulation.

[8]  W. Weintraub,et al.  Predictors of groin complications after balloon and new-device coronary intervention. , 1995, The American journal of cardiology.

[9]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[10]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[11]  R. Califf,et al.  Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months , 1994, The Lancet.

[12]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[13]  D. Pilcher,et al.  Vascular complications of cardiac catheterization. , 1994, American journal of surgery.

[14]  M. Leon,et al.  Vascular Complications After Balloon and New Device Angioplasty , 1993, Circulation.

[15]  Robert Gray,et al.  Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer Prognosis , 1992 .

[16]  S. Batra,et al.  Influence of arterial access sites and interventional procedures on vascular complications after cardiac catheterizations. , 1992, American journal of surgery.

[17]  E. Topol,et al.  Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. , 1992, The American journal of cardiology.

[18]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.

[19]  R. B. Smith,et al.  Postcatheterization vascular complications associated with percutaneous transluminal coronary angioplasty. , 1990, Journal of vascular surgery.

[20]  J. Richardson,et al.  Peripheral vascular complications of coronary angioplasty. , 1989, The American surgeon.

[21]  A. Moreyra,et al.  Peripheral Vascular Complications from Percutaneous Transluminal Coronary Angioplasty: A Comparison with Transfemoral Cardiac Catheterization , 1989, The American journal of the medical sciences.

[22]  D. Baim,et al.  Vascular Complications of Percutaneous Femoral Cardiac Interventions: Incidence and Operative Repair , 1988 .

[23]  E F Cook,et al.  Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. , 1987, The American journal of medicine.

[24]  B. Efron.  Estimating the Error Rate of a Prediction Rule: Improvement on Cross-Validation , 1983 .